Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease

By T. Outeiro, E. Kontopoulos, Stephen M. Altmann, Irina Kufareva, K. Strathearn, A. Amore, Catherine B. Volk, M. Maxwell, J. Rochet, P. McLean and 5 more. Science, 2007

961 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Geriatrics and Gerontology, Neurology

View Paper: https://www.semanticscholar.org/paper/a29fd3421de18a194b63f81acbd06a332aeaeed4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Leonidas Stefanis

In Geriatrics and Gerontology

1. Minoru Yoshida
2. E. Seto

In Neurology

1. Leonidas Stefanis

Citations in the corpus

• α-Synuclein in Parkinson's disease. (2012, background): “…neuroprotection in various models of synucleinopathy, although whether potential acetylation effects on histone were involved was not ascertained (Outeiro et al. 2007). a-SYNUCLEIN OUTSIDE THE CELL: THE THEORY OF PROPAGATION Although initially a-synuclein was thought to be a purely intracellular…”
• Erasers of histone acetylation: the histone deacetylase enzymes. (2014, background): “For example, SIRT2 deacetylates a-tubulin, and may promote a-synuclein toxicity and modified inclusion morphology in Parkinson’s disease (Outeiro et al. 2007).”